The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of ... Financial Post Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy ... Market opening: Biogen Idec up after positive MS drug study |
